{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:54:25Z","timestamp":1789095265758,"version":"build-2803163510"},"reference-count":210,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010446","name":"Institute for Basic Science","doi-asserted-by":"publisher","award":["IBS-R022-D1"],"award-info":[{"award-number":["IBS-R022-D1"]}],"id":[{"id":"10.13039\/501100010446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Genomic instability and the accumulation of DNA damage are hallmarks of cancer, often resulting from defects in DNA repair pathways. While normal cells rely on highly coordinated DNA damage response (DDR) mechanisms to maintain genomic integrity, cancer cells exploit aberrant DDR regulation to sustain uncontrolled proliferation and survival. Despite significant advancements in chemotherapy, targeted therapy, and immunotherapy, the emergence of resistance remains a major challenge in cancer treatment. Small molecule inhibitors targeting key DDR proteins have emerged as promising therapeutic agents, not only as direct anticancer drugs but also as indispensable tools for dissecting the molecular intricacies of DNA repair. Recent therapeutic approaches leverage synthetic lethality and DDR pathway vulnerabilities to selectively eradicate tumor cells while minimizing damage to normal tissues. These inhibitors provide insights into mechanisms of tumor resistance, facilitating the rational design of combination therapies to enhance treatment efficacy. This review examines the latest advancements in DNA repair-targeted therapeutics, with a focus on small molecule inhibitors currently under clinical investigation. Additionally, we discuss emerging strategies for optimizing DDR-targeted interventions, including biomarker-driven patient selection and rational drug combinations. Understanding these molecular interactions will contribute to the development of novel, more effective treatment paradigms for cancer therapy.<\/jats:p>","DOI":"10.1093\/narcan\/zcaf040","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:06:19Z","timestamp":1759320379000},"source":"Crossref","is-referenced-by-count":12,"title":["Targeting DNA repair mechanisms in cancer therapy: the role of small molecule DNA repair inhibitors"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7529-8212","authenticated-orcid":false,"given":"Seula","family":"Jeong","sequence":"first","affiliation":[{"name":"Center for Genomic Integrity, Institute for Basic Science , Ulsan 44919 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3262-7831","authenticated-orcid":false,"given":"Yuheon","family":"Chung","sequence":"additional","affiliation":[{"name":"Center for Genomic Integrity, Institute for Basic Science , Ulsan 44919 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8036-4331","authenticated-orcid":false,"given":"Soomin","family":"Heo","sequence":"additional","affiliation":[{"name":"Center for Genomic Integrity, Institute for Basic Science , Ulsan 44919 ,","place":["Republic of Korea"]},{"name":"Ulsan National Institute of Science and Technology Department of Biomedical Engineering, , Ulsan 44919 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-6190","authenticated-orcid":false,"given":"Kyungjae","family":"Myung","sequence":"additional","affiliation":[{"name":"Center for Genomic Integrity, Institute for Basic Science , Ulsan 44919 ,","place":["Republic of Korea"]},{"name":"Ulsan National Institute of Science and Technology Department of Biomedical Engineering, , Ulsan 44919 ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"2025110311355120200_B1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2025110311355120200_B2","doi-asserted-by":"publisher","first-page":"a012583","DOI":"10.1101\/cshperspect.a012583","article-title":"Base excision repair","volume":"5","author":"Krokan","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2025110311355120200_B3","doi-asserted-by":"publisher","first-page":"10524","DOI":"10.1074\/jbc.TM118.000372","article-title":"Homologous recombination and the repair of DNA double-strand breaks","volume":"293","author":"Wright","year":"2018","journal-title":"J Biol Chem"},{"key":"2025110311355120200_B4","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"2025110311355120200_B5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2045-3701-3-11","article-title":"The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy","volume":"3","author":"Zhang","year":"2013","journal-title":"Cell Biosci"},{"key":"2025110311355120200_B6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev.biochem.052308.093131","article-title":"The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway","volume":"79","author":"Lieber","year":"2010","journal-title":"Annu Rev Biochem"},{"key":"2025110311355120200_B7","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.4161\/cc.7.18.6679","article-title":"DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells","volume":"7","author":"Mao","year":"2008","journal-title":"Cell Cycle"},{"key":"2025110311355120200_B8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Mol Oncol"},{"key":"2025110311355120200_B9","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.molcel.2016.06.020","article-title":"Essential roles for polymerase \u03b8-mediated end joining in the repair of chromosome breaks","volume":"63","author":"Wyatt","year":"2016","journal-title":"Mol Cell"},{"key":"2025110311355120200_B10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1086\/279847","article-title":"The origin of variations in sexual and sex-limited characters","volume":"56","author":"Bridges","year":"1922","journal-title":"Am Nat"},{"key":"2025110311355120200_B11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"2025110311355120200_B12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCAMutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"2025110311355120200_B13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrc1011","article-title":"ATM and related protein kinases: safeguarding genome integrity","volume":"3","author":"Shiloh","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2025110311355120200_B14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nature01368","article-title":"DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation","volume":"421","author":"Bakkenist","year":"2003","journal-title":"Nature"},{"key":"2025110311355120200_B15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11523-025-01136-6","article-title":"The development of ATM inhibitors in cancer therapy","volume":"20","author":"Ampolini","year":"2025","journal-title":"Targ Oncol"},{"key":"2025110311355120200_B16","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1021\/acs.molpharmaceut.1c00166","article-title":"Sensors and inhibitors for the detection of ataxia telangiectasia mutated (ATM) protein kinase","volume":"18","author":"Huang","year":"2021","journal-title":"Mol Pharmaceutics"},{"key":"2025110311355120200_B17","doi-asserted-by":"publisher","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","article-title":"Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM","volume":"64","author":"Hickson","year":"2004","journal-title":"Cancer Res"},{"key":"2025110311355120200_B18","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/s41598-023-28185-z","article-title":"ATM inhibitor KU60019 synergistically sensitizes lung cancer cells to topoisomerase II poisons by multiple mechanisms","volume":"13","author":"Shu","year":"2023","journal-title":"Sci Rep"},{"key":"2025110311355120200_B19","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1158\/1535-7163.MCT-09-0519","article-title":"Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion","volume":"8","author":"Golding","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"2025110311355120200_B20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ijc.28680","article-title":"Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019","volume":"135","author":"Vecchio","year":"2014","journal-title":"Int J Cancer"},{"key":"2025110311355120200_B21","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1021\/acschembio.8b01020","article-title":"Chemoproteomic selectivity profiling of PIKK and PI3K kinase inhibitors","volume":"14","author":"Reinecke","year":"2019","journal-title":"ACS Chem Biol"},{"key":"2025110311355120200_B22","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1158\/1535-7163.MCT-20-0502","article-title":"Radiopotentiation profiling of multiple inhibitors of the DNA damage response for early clinical development","volume":"20","author":"Gill","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2025110311355120200_B23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1158\/1535-7163.MCT-18-1394","article-title":"Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses preclinically","volume":"19","author":"Riches","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2025110311355120200_B24","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1186\/s12885-022-10084-7","article-title":"ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer","volume":"22","author":"Davis","year":"2022","journal-title":"BMC Cancer"},{"key":"2025110311355120200_B25","doi-asserted-by":"publisher","first-page":"eaat1719","DOI":"10.1126\/sciadv.aat1719","article-title":"The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models","volume":"4","author":"Durant","year":"2018","journal-title":"Sci Adv"},{"key":"2025110311355120200_B26","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuonc\/noaa238","article-title":"Brain exposure of the ATM inhibitor AZD1390 in humans\u2014a positron emission tomography study","volume":"23","author":"Jucaite","year":"2021","journal-title":"Neuro Oncol"},{"key":"2025110311355120200_B27","doi-asserted-by":"publisher","first-page":"7466","DOI":"10.1158\/0008-5472.CAN-08-0763","article-title":"Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation","volume":"68","author":"Rainey","year":"2008","journal-title":"Cancer Res"},{"key":"2025110311355120200_B28","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1158\/1078-0432.CCR-23-0290","article-title":"ATM-inhibitor AZD1390 is a radiosensitizer for breast cancer CNS metastasis","volume":"29","author":"Tew","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025110311355120200_B29","doi-asserted-by":"publisher","first-page":"viii88","DOI":"10.1093\/neuonc\/noae165.0349","article-title":"Ctim-16. SAFETY and preliminary efficacy of Azd1390 + radiation therapy for glioblastoma","volume":"26","author":"Wen","year":"2024","journal-title":"Neuro Oncol"},{"key":"2025110311355120200_B30","doi-asserted-by":"publisher","first-page":"e139333","DOI":"10.1172\/JCI139333","article-title":"ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS\/STING activation","volume":"131","author":"Hu","year":"2021","journal-title":"J Clin Invest"},{"key":"2025110311355120200_B31","doi-asserted-by":"publisher","first-page":"zcaa024","DOI":"10.1093\/narcan\/zcaa024","article-title":"Regulation and pharmacological targeting of RAD51 in cancer","volume":"2","author":"Grundy","year":"2020","journal-title":"NAR Cancer"},{"key":"2025110311355120200_B32","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.dnarep.2007.12.008","article-title":"The consequences of Rad51 overexpression for normal and tumor cells","volume":"7","author":"Klein","year":"2008","journal-title":"DNA Repair"},{"key":"2025110311355120200_B33","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1021\/acs.jmedchem.9b01526","article-title":"Synthetic lethality in pancreatic cancer: discovery of a new RAD51\u2013BRCA2 small molecule disruptor that inhibits homologous recombination and synergizes with Olaparib","volume":"63","author":"Bagnolini","year":"2020","journal-title":"J Med Chem"},{"key":"2025110311355120200_B34","doi-asserted-by":"publisher","first-page":"5782","DOI":"10.1021\/jm1002974","article-title":"Design of potent inhibitors of Human RAD51 recombinase based on BRC motifs of BRCA2 protein: modeling and experimental validation of a Chimera peptide","volume":"53","author":"Nomme","year":"2010","journal-title":"J Med Chem"},{"key":"2025110311355120200_B35","doi-asserted-by":"crossref","first-page":"935593","DOI":"10.3389\/fonc.2022.935593","article-title":"The emerging roles of Rad51 in cancer and its potential as a therapeutic target","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"2025110311355120200_B36","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1021\/cb100428c","article-title":"Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening","volume":"6","author":"Huang","year":"2011","journal-title":"ACS Chem Biol"},{"key":"2025110311355120200_B37","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3390\/genes12060920","article-title":"New RAD51 inhibitors to target homologous recombination in Human cells","volume":"12","author":"Shkundina","year":"2021","journal-title":"Genes"},{"key":"2025110311355120200_B38","doi-asserted-by":"crossref","first-page":"885186","DOI":"10.3389\/fonc.2022.885186","article-title":"Targeting the homologous recombination pathway in cancer with a novel class of RAD51 inhibitors","volume":"12","author":"Gu","year":"2022","journal-title":"Front Oncol"},{"key":"2025110311355120200_B39","doi-asserted-by":"publisher","first-page":"e100993","DOI":"10.1371\/journal.pone.0100993","article-title":"A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts","volume":"9","author":"Huang","year":"2014","journal-title":"PLoS One"},{"key":"2025110311355120200_B40","doi-asserted-by":"publisher","first-page":"7347","DOI":"10.1093\/nar\/gks353","article-title":"RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells","volume":"40","author":"Budke","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"2025110311355120200_B41","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3892\/or.2017.5724","article-title":"The homologous recombination protein RAD51 is a promising therapeutic target for cervical carcinoma","volume":"38","author":"Chen","year":"2017","journal-title":"Oncol Rep"},{"key":"2025110311355120200_B42","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.stemcr.2016.12.005","article-title":"RAD51 Is a selective DNA repair target to radiosensitize glioma stem cells","volume":"8","author":"King","year":"2017","journal-title":"Stem Cell Rep"},{"key":"2025110311355120200_B43","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1021\/jm301565b","article-title":"An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity","volume":"56","author":"Budke","year":"2013","journal-title":"J Med Chem"},{"key":"2025110311355120200_B44","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1093\/nar\/gkl550","article-title":"A dynamic model for replication protein A (RPA) function in DNA processing pathways","volume":"34","author":"Fanning","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"2025110311355120200_B45","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/jcp.20622","article-title":"Functions of human replication protein A (RPA): from DNA replication to DNA damage and stress responses","volume":"208","author":"Zou","year":"2006","journal-title":"J Cell Physiol"},{"key":"2025110311355120200_B46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/cr.2014.147","article-title":"RPA-coated single-stranded DNA as a platform for post-translational modifications in the DNA damage response","volume":"25","author":"Mar\u00e9chal","year":"2015","journal-title":"Cell Res"},{"key":"2025110311355120200_B47","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","article-title":"ATR prohibits replication catastrophe by preventing global exhaustion of RPA","volume":"155","author":"Toledo","year":"2013","journal-title":"Cell"},{"key":"2025110311355120200_B48","doi-asserted-by":"publisher","first-page":"19095","DOI":"10.1074\/jbc.M800881200","article-title":"Cellular functions of human RPA1: multiple roles of domains in replication, repair, and checkpoints*","volume":"283","author":"Haring","year":"2008","journal-title":"J Biol Chem"},{"key":"2025110311355120200_B49","doi-asserted-by":"publisher","first-page":"826655","DOI":"10.3389\/fonc.2022.826655","article-title":"In vivo targeting replication protein A for cancer therapy","volume":"12","author":"VanderVere-Carozza","year":"2022","journal-title":"Front Oncol"},{"key":"2025110311355120200_B50","doi-asserted-by":"publisher","first-page":"19791","DOI":"10.1038\/s41598-024-70589-y","article-title":"The effect of replication protein A inhibition and post-translational modification on ATR kinase signaling","volume":"14","author":"Jordan","year":"2024","journal-title":"Sci Rep"},{"key":"2025110311355120200_B51","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1016\/j.bmc.2011.03.012","article-title":"Small molecule inhibitor of the RPA70 N-terminal protein interaction domain discovered using in silico and in vitro methods","volume":"19","author":"Glanzer","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"2025110311355120200_B52","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1093\/nar\/gks1291","article-title":"A small molecule directly inhibits the p53 transactivation domain from binding to replication protein A","volume":"41","author":"Glanzer","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"2025110311355120200_B53","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1158\/0008-5472.CAN-14-0306","article-title":"RPA inhibition increases replication stress and suppresses tumor growth","volume":"74","author":"Glanzer","year":"2014","journal-title":"Cancer Res"},{"key":"2025110311355120200_B54","doi-asserted-by":"publisher","first-page":"14941","DOI":"10.3390\/ijms241914941","article-title":"Chemical inhibition of RPA by HAMNO alters cell cycle dynamics by impeding DNA replication and G2-to-M transition but has little effect on the radiation-induced DNA damage response","volume":"24","author":"Dueva","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025110311355120200_B55","doi-asserted-by":"publisher","first-page":"zcaa022","DOI":"10.1093\/narcan\/zcaa022","article-title":"Replication protein A: a multifunctional protein with roles in DNA replication, repair and beyond","volume":"2","author":"Dueva","year":"2020","journal-title":"NAR Cancer"},{"key":"2025110311355120200_B56","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-09-3422","article-title":"Targeted inhibition of replication protein A reveals cytotoxic activity, synergy with chemotherapeutic DNA-damaging agents, and insight into cellular function","volume":"70","author":"Shuck","year":"2010","journal-title":"Cancer Res"},{"key":"2025110311355120200_B57","first-page":"5545","article-title":"Abstract #5545: the effect of a small molecule inhibitor of Replication Protein A (TDRL-505) on DNA binding, cellular function and platinum sensitivity","volume":"69","author":"Shuck","year":"2009","journal-title":"Cancer Res"},{"key":"2025110311355120200_B58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bcp.2014.10.013","article-title":"Chemical inhibitor targeting the replication protein A\u2013DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer","volume":"93","author":"Mishra","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"2025110311355120200_B59","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nsmb1313","article-title":"The structure-specific endonuclease Mus81 contributes to replication restart by generating double-strand DNA breaks","volume":"14","author":"Hanada","year":"2007","journal-title":"Nat Struct Mol Biol"},{"key":"2025110311355120200_B60","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nature16139","article-title":"Replication stress activates DNA repair synthesis in mitosis","volume":"528","author":"Minocherhomji","year":"2015","journal-title":"Nature"},{"key":"2025110311355120200_B61","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1158\/1535-7163.MCT-18-0833","article-title":"The DNA endonuclease Mus81 regulates ZEB1 expression and serves as a target of BET4 inhibitors in gastric cancer","volume":"18","author":"Yin","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"2025110311355120200_B62","doi-asserted-by":"crossref","first-page":"844135","DOI":"10.3389\/fonc.2022.844135","article-title":"MUS81 inhibition enhances the anticancer efficacy of Talazoparib by impairing ATR\/CHK1 signaling pathway in gastric cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"2025110311355120200_B63","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1021\/acsmedchemlett.3c00453","article-title":"Fragment-based discovery of novel MUS81 inhibitors","volume":"15","author":"Collie","year":"2024","journal-title":"ACS Med Chem Lett"},{"key":"2025110311355120200_B64","doi-asserted-by":"publisher","first-page":"zcaf013","DOI":"10.1093\/narcan\/zcaf013","article-title":"Synergistic enhancement of PARP inhibition via small molecule UNI66-mediated suppression of BRD4-dependent transcription of RAD51 and CtIP","volume":"7","author":"Amarsanaa","year":"2025","journal-title":"NAR Cancer"},{"key":"2025110311355120200_B65","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1158\/1535-7163.MCT-23-0065","article-title":"First-in-human study of AZD5153, A small-molecule inhibitor of bromodomain protein 4, in patients with relapsed\/refractory malignant solid tumors and lymphoma","volume":"22","author":"Hamilton","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2025110311355120200_B66","doi-asserted-by":"crossref","first-page":"853652","DOI":"10.3389\/fcell.2022.853652","article-title":"AZD5153, a bivalent BRD4 inhibitor, suppresses hepatocarcinogenesis by altering BRD4 chromosomal landscape and modulating the transcriptome of HCC cells","volume":"10","author":"Lin","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"2025110311355120200_B67","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.tig.2024.02.006","article-title":"PCNA cycling dynamics during DNA replication and repair in mammals","volume":"40","author":"Kang","year":"2024","journal-title":"Trends Genet"},{"key":"2025110311355120200_B68","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1016\/j.febslet.2010.09.021","article-title":"Proliferating cell nuclear antigen in the cytoplasm interacts with components of glycolysis and cancer","volume":"584","author":"Naryzhny","year":"2010","journal-title":"FEBS Lett"},{"key":"2025110311355120200_B69","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.1158\/1078-0432.CCR-18-0592","article-title":"The anticancer activity of a first-in-class small-molecule targeting PCNA","volume":"24","author":"Gu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025110311355120200_B70","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1158\/1535-7163.MCT-10-0778","article-title":"Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth","volume":"10","author":"Zhao","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2025110311355120200_B71","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.chembiol.2023.07.001","article-title":"Small molecule targeting of transcription-replication conflict for selective chemotherapy","volume":"30","author":"Gu","year":"2023","journal-title":"Cell Chem Biol"},{"key":"2025110311355120200_B72","doi-asserted-by":"publisher","first-page":"6876","DOI":"10.1158\/1538-7445.AM2025-6876","article-title":"Abstract 6876: a novel PCNA inhibitor AOH1996 demonstrates pre-clinical efficacy in pancreatic ductal adenocarcinoma models","volume":"85","author":"Bannoura","year":"2025","journal-title":"Cancer Res"},{"key":"2025110311355120200_B73","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1158\/1538-7445.AM2025-3864","article-title":"Abstract 3864: AOH1996: a multi-faceted inhibitor of metastasis via PCNA and tumor microenvironment targeting","volume":"85","author":"Lingeman","year":"2025","journal-title":"Cancer Res"},{"key":"2025110311355120200_B74","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41388-022-02582-6","article-title":"ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a phase 1 study","volume":"42","author":"Lemech","year":"2023","journal-title":"Oncogene"},{"key":"2025110311355120200_B75","doi-asserted-by":"publisher","first-page":"15847","DOI":"10.1038\/ncomms15847","article-title":"Structural insights into the function of ZRANB3 in replication stress response","volume":"8","author":"Sebesta","year":"2017","journal-title":"Nat Commun"},{"key":"2025110311355120200_B76","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/cancers14020289","article-title":"ATX-101, a peptide targeting PCNA, has antitumor efficacy alone or in combination with radiotherapy in murine models of human glioblastoma","volume":"14","author":"Gravina","year":"2022","journal-title":"Cancers"},{"key":"2025110311355120200_B77","doi-asserted-by":"crossref","first-page":"32448","DOI":"10.18632\/oncotarget.25963","article-title":"\u201cTwo hits - one stone\u201d; increased efficacy of cisplatin-based therapies by targeting PCNA\u2019s role in both DNA repair and cellular signaling","volume":"9","author":"Krogh\u00a0S\u00f8gaard","year":"2018","journal-title":"Oncotarget"},{"key":"2025110311355120200_B78","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1476-4598-12-91","article-title":"USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy","volume":"12","author":"Garc\u00eda-Santisteban","year":"2013","journal-title":"Mol Cancer"},{"key":"2025110311355120200_B79","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.molcel.2005.01.008","article-title":"The deubiquitinating enzyme USP1 regulates the fanconi anemia pathway","volume":"17","author":"Nijman","year":"2005","journal-title":"Mol Cell"},{"key":"2025110311355120200_B80","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41467-019-10408-5","article-title":"DNA requirement in FANCD2 deubiquitination by USP1\u2013UAF1\u2013RAD51AP1 in the Fanconi anemia DNA damage response","volume":"10","author":"Liang","year":"2019","journal-title":"Nat Commun"},{"key":"2025110311355120200_B81","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1158\/0008-5472.CAN-24-0293","article-title":"The USP1 inhibitor KSQ-4279 overcomes PARP inhibitor resistance in homologous recombination\u2013Deficient tumors","volume":"84","author":"Cadzow","year":"2024","journal-title":"Cancer Res"},{"key":"2025110311355120200_B82","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nchembio.1455","article-title":"A selective USP1\u2013UAF1 inhibitor links deubiquitination to DNA damage responses","volume":"10","author":"Liang","year":"2014","journal-title":"Nat Chem Biol"},{"key":"2025110311355120200_B83","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10495-022-01736-x","article-title":"ML323, a USP1 inhibitor triggers cell cycle arrest, apoptosis and autophagy in esophageal squamous cell carcinoma cells","volume":"27","author":"Sun","year":"2022","journal-title":"Apoptosis"},{"key":"2025110311355120200_B84","first-page":"174","article-title":"The deubiquitinating enzyme USP1 is auto-ubiquitinated and destabilized by ML323 in colorectal cancer cells","volume":"7","author":"Xu","year":"2023","journal-title":"EJMO"},{"key":"2025110311355120200_B85","doi-asserted-by":"publisher","first-page":"15557","DOI":"10.1021\/acs.jmedchem.4c01184","article-title":"Structural and biochemical insights into the mechanism of action of the clinical USP1 inhibitor, KSQ-4279","volume":"67","author":"Rennie","year":"2024","journal-title":"J Med Chem"},{"key":"2025110311355120200_B86","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1200\/JCO.2024.42.16_suppl.3005","article-title":"First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations","volume":"42","author":"Yap","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025110311355120200_B87","doi-asserted-by":"publisher","first-page":"ND01","DOI":"10.1158\/1538-7445.AM2022-ND01","article-title":"Abstract ND01: KSQ-4279: A first-in-class USP1 inhibitor for the treatment of cancers with homologous recombination deficiencies","volume":"82","author":"Cadzow","year":"2022","journal-title":"Cancer Res"},{"key":"2025110311355120200_B88","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1158\/1538-7445.AM2024-670","article-title":"Abstract 670: preclinical candidate LAE120, a novel selective USP1 inhibitor shows effective anticancer and combination activity with PARP inhibitor","volume":"84","author":"Wang","year":"2024","journal-title":"Cancer Res"},{"key":"2025110311355120200_B89","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1158\/1538-7445.AM2023-502","article-title":"Abstract 502: ISM3091, a novel selective USP1 inhibitor as a targeted anticancer therapy","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res"},{"key":"2025110311355120200_B90","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat Chem Biol"},{"key":"2025110311355120200_B91","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1016\/j.celrep.2016.12.031","article-title":"Cancer-specific synthetic lethality between ATR and CHK1 kinase activities","volume":"17","author":"Sanjiv","year":"2016","journal-title":"Cell Rep"},{"key":"2025110311355120200_B92","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/nsmb.2189","article-title":"Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors","volume":"18","author":"Murga","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"2025110311355120200_B93","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1111\/cas.15845","article-title":"Emerging strategies for cancer therapy by ATR inhibitors","volume":"114","author":"Yano","year":"2023","journal-title":"Cancer Sci"},{"key":"2025110311355120200_B94","doi-asserted-by":"publisher","first-page":"13837","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat Commun"},{"key":"2025110311355120200_B95","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41416-021-01406-w","article-title":"Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours","volume":"125","author":"Shapiro","year":"2021","journal-title":"Br J Cancer"},{"key":"2025110311355120200_B96","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I study of ATR inhibitor M6620 in combination with Topotecan in patients with advanced solid tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"JCO"},{"key":"2025110311355120200_B97","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1158\/0008-5472.CAN-13-3369","article-title":"ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase I inhibitors by disabling DNA replication initiation and fork elongation responses","volume":"74","author":"Joss\u00e9","year":"2014","journal-title":"Cancer Res"},{"key":"2025110311355120200_B98","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","article-title":"Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours","volume":"125","author":"Middleton","year":"2021","journal-title":"Br J Cancer"},{"key":"2025110311355120200_B99","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2023.4025","article-title":"Berzosertib plus Topotecan vs Topotecan alone in patients with relapsed small cell lung cancer: a randomized clinical trial","volume":"9","author":"Takahashi","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025110311355120200_B100","doi-asserted-by":"publisher","first-page":"107518","DOI":"10.1016\/j.pharmthera.2020.107518","article-title":"Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): clinical candidate for cancer therapy","volume":"210","author":"Gorecki","year":"2020","journal-title":"Pharmacol Ther"},{"key":"2025110311355120200_B101","doi-asserted-by":"publisher","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and characterization of AZD6738, a potent inhibitor of Ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent","volume":"61","author":"Foote","year":"2018","journal-title":"J. Med. Chem."},{"key":"2025110311355120200_B102","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00280-021-04388-x","article-title":"Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice","volume":"89","author":"Kiesel","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025110311355120200_B103","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","article-title":"Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a phase I study","volume":"27","author":"Yap","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025110311355120200_B104","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1158\/1078-0432.CCR-21-0251","article-title":"Phase I study of Ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly Paclitaxel in refractory cancer","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025110311355120200_B105","doi-asserted-by":"publisher","first-page":"eado4618","DOI":"10.1126\/sciadv.ado4618","article-title":"ATR inhibition activates cancer cell cGAS\/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer","volume":"10","author":"Taniguchi","year":"2024","journal-title":"Sci Adv"},{"key":"2025110311355120200_B106","doi-asserted-by":"crossref","first-page":"e000340","DOI":"10.1136\/jitc-2019-000340","article-title":"ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma","volume":"8","author":"Hailong","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025110311355120200_B107","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy","volume":"33","author":"Kim","year":"2022","journal-title":"Ann Oncol"},{"key":"2025110311355120200_B108","doi-asserted-by":"crossref","first-page":"e005041","DOI":"10.1136\/jitc-2022-005041","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer","volume":"10","author":"Minsuk","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025110311355120200_B109","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-Human trial of the oral Ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"key":"2025110311355120200_B110","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1535-7163.MCT-23-0094","article-title":"Elimusertib has antitumor activity in preclinical patient-derived pediatric solid tumor models","volume":"23","author":"Pusch","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"2025110311355120200_B111","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ygyno.2022.11.014","article-title":"Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma","volume":"168","author":"Harold","year":"2023","journal-title":"Gynecol Oncol"},{"key":"2025110311355120200_B112","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1200\/JCO.2024.42.16_suppl.3076","article-title":"A phase I study of ATR inhibitor BAY1895344 (elimusertib) plus topotecan (ETCTN 10402): results of dose escalation","volume":"42","author":"Stockton","year":"2024","journal-title":"JCO"},{"key":"2025110311355120200_B113","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1158\/2159-8290.CD-24-1500","article-title":"Phase ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects","volume":"15","author":"Yap","year":"2025","journal-title":"Cancer Discov"},{"key":"2025110311355120200_B114","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents","volume":"20","author":"Jo","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2025110311355120200_B115","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat Med"},{"key":"2025110311355120200_B116","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1021\/acs.jmedchem.3c01917","article-title":"Discovery of the potent and selective ATR inhibitor Camonsertib (RP-3500)","volume":"67","author":"Black","year":"2024","journal-title":"J Med Chem"},{"key":"2025110311355120200_B117","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1093\/nar\/gkv160","article-title":"Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation","volume":"43","author":"Bakr","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2025110311355120200_B118","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/ijc.35164","article-title":"Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse","volume":"156","author":"Mann","year":"2025","journal-title":"Int J Cancer"},{"key":"2025110311355120200_B119","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1200\/JCO.2021.39.15_suppl.3006","article-title":"First-in-human phase I\/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers","volume":"39","author":"Lynch","year":"2021","journal-title":"JCO"},{"key":"2025110311355120200_B120","doi-asserted-by":"publisher","first-page":"P2","DOI":"10.1158\/1538-7445.SABCS19-P2-05-05","article-title":"Abstract P2-05-05: RAD51 inhibition using CYT-0851, shows anti-cancer activity in cellular models of breast cancer and acts synergistically with PARP inhibitors","volume":"80","author":"Guy","year":"2020","journal-title":"Cancer Res"},{"key":"2025110311355120200_B121","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2147\/OTT.S322297","article-title":"Targeting RAD51-mediated homologous recombination as a treatment for advanced solid and hematologic malignancies: opportunities and challenges ahead","volume":"15","author":"Tsang","year":"2022","journal-title":"OTT"},{"key":"2025110311355120200_B122","doi-asserted-by":"publisher","first-page":"e9172","DOI":"10.15252\/emmm.201809172","article-title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","volume":"10","author":"Castroviejo-Bermejo","year":"2018","journal-title":"EMBO Mol Med"},{"key":"2025110311355120200_B123","doi-asserted-by":"publisher","first-page":"e0266645","DOI":"10.1371\/journal.pone.0266645","article-title":"RAD51 is a druggable target that sustains replication fork progression upon DNA replication stress","volume":"17","author":"Feu","year":"2022","journal-title":"PLoS One"},{"key":"2025110311355120200_B124","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41417-024-00815-2","article-title":"Pol\u03b8: emerging synthetic lethal partner in homologous recombination-deficient tumors","volume":"31","author":"Bazan\u00a0Russo","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"2025110311355120200_B125","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1146\/annurev-genet-072920-041046","article-title":"Genome protection by DNA polymerase \u03b8","volume":"56","author":"Wood","year":"2022","journal-title":"Annu Rev Genet"},{"key":"2025110311355120200_B126","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nsmb.3494","article-title":"The helicase domain of Pol\u03b8 counteracts RPA to promote alt-NHEJ","volume":"24","author":"Mateos-Gomez","year":"2017","journal-title":"Nat Struct Mol Biol"},{"key":"2025110311355120200_B127","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s43018-021-00203-x","article-title":"A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors","volume":"2","author":"Zhou","year":"2021","journal-title":"Nat Cancer"},{"key":"2025110311355120200_B128","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1038\/s41467-021-23463-8","article-title":"Pol\u03b8 inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance","volume":"12","author":"Zatreanu","year":"2021","journal-title":"Nat Commun"},{"key":"2025110311355120200_B129","doi-asserted-by":"publisher","first-page":"6498","DOI":"10.1021\/acs.jmedchem.2c02101","article-title":"Small molecules targeting DNA polymerase theta (POL\u03b8) as promising synthetic lethal agents for precision cancer therapy","volume":"66","author":"Pismataro","year":"2023","journal-title":"J Med Chem"},{"key":"2025110311355120200_B130","doi-asserted-by":"publisher","first-page":"CT169","DOI":"10.1158\/1538-7445.AM2024-CT169","article-title":"Abstract CT169: first-in-human, phase 1\/2 study of GSK4524101, an oral DNA polymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors","volume":"84","author":"Samnotra","year":"2024","journal-title":"Cancer Res"},{"key":"2025110311355120200_B131","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/cells9010238","article-title":"Prevention of DNA replication stress by CHK1 leads to chemoresistance despite a DNA repair defect in homologous recombination in breast cancer","volume":"9","author":"Meyer","year":"2020","journal-title":"Cells"},{"key":"2025110311355120200_B132","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1016\/j.molcel.2021.08.009","article-title":"A basal-level activity of ATR links replication fork surveillance and stress response","volume":"81","author":"Yin","year":"2021","journal-title":"Mol Cell"},{"key":"2025110311355120200_B133","doi-asserted-by":"publisher","first-page":"e56530","DOI":"10.15252\/embr.202256530","article-title":"CHK1-CDC25A-CDK1 regulate cell cycle progression and protect genome integrity in early mouse embryos","volume":"24","author":"Knoblochova","year":"2023","journal-title":"EMBO Rep"},{"key":"2025110311355120200_B134","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jtho.2019.01.028","article-title":"Checkpoint kinase 1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in SCLC by promoting mitotic cell death","volume":"14","author":"Hsu","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2025110311355120200_B135","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1021\/acsptsci.0c00201","article-title":"Comparative activity and off-target effects in cells of the CHK1 inhibitors MK-8776, SRA737, and LY2606368","volume":"4","author":"Ditano","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2025110311355120200_B136","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1158\/1535-7163.MCT-14-1037","article-title":"LY2606368 Causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms","volume":"14","author":"King","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"2025110311355120200_B137","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1158\/0008-5472.CAN-20-1439","article-title":"Targeting the PI3K\/mTOR pathway augments CHK1 inhibitor\u2013induced replication stress and antitumor activity in high-grade serous ovarian cancer","volume":"80","author":"Huang","year":"2020","journal-title":"Cancer Res"},{"key":"2025110311355120200_B138","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1038\/s41388-020-1383-4","article-title":"Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer","volume":"39","author":"Nair","year":"2020","journal-title":"Oncogene"},{"key":"2025110311355120200_B139","doi-asserted-by":"publisher","first-page":"111026","DOI":"10.18632\/oncotarget.22195","article-title":"Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer","volume":"8","author":"Brill","year":"2017","journal-title":"Oncotarget"},{"key":"2025110311355120200_B140","doi-asserted-by":"publisher","first-page":"6127","DOI":"10.1158\/1078-0432.CCR-19-0448","article-title":"The CHK1 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition","volume":"25","author":"Parmar","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025110311355120200_B141","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1158\/1078-0432.CCR-17-3347","article-title":"Evaluation of Prexasertib, a checkpoint kinase 1 inhibitor, in a phase Ib study of patients with squamous cell carcinoma","volume":"24","author":"Hong","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025110311355120200_B142","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(18)30009-3","article-title":"Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study","volume":"19","author":"Lee","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025110311355120200_B143","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1158\/1535-7163.MCT-19-0946","article-title":"CHK1\/2 Inhibitor prexasertib suppresses NOTCH signaling and enhances cytotoxicity of cisplatin and radiation in head and neck squamous cell carcinoma","volume":"19","author":"Zeng","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2025110311355120200_B144","first-page":"689","article-title":"Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S\u20131","volume":"43","author":"Morimoto","year":"2020","journal-title":"Oncol Rep"},{"key":"2025110311355120200_B145","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1038\/s41467-024-47215-6","article-title":"The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial","volume":"15","author":"Giudice","year":"2024","journal-title":"Nat Commun"},{"key":"2025110311355120200_B146","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1200\/JCO.2015.64.5788","article-title":"Phase I study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced cancer","volume":"34","author":"Hong","year":"2016","journal-title":"JCO"},{"key":"2025110311355120200_B147","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ygyno.2022.09.019","article-title":"A phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer","volume":"167","author":"Konstantinopoulos","year":"2022","journal-title":"Gynecol Oncol"},{"key":"2025110311355120200_B148","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1634\/theoncologist.2020-0491","article-title":"A phase II single arm pilot study of the CHK1 inhibitor prexasertib (LY2606368) in BRCA wild-type, advanced triple-negative breast cancer","volume":"25","author":"Gatti-Mays","year":"2020","journal-title":"Oncologist"},{"key":"2025110311355120200_B149","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1158\/1078-0432.CCR-20-3242","article-title":"Preclinical evaluation and Phase Ib study of Prexasertib, a CHK1 inhibitor, and Samotolisib (LY3023414), a dual PI3K\/mTOR inhibitor","volume":"27","author":"Hong","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025110311355120200_B150","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s11523-021-00835-0","article-title":"A phase 1b trial of Prexasertib in combination with standard-of-care agents in advanced or metastatic cancer","volume":"16","author":"Moore","year":"2021","journal-title":"Targ Oncol"},{"key":"2025110311355120200_B151","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-18-2728","article-title":"Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models","volume":"25","author":"Lowery","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025110311355120200_B152","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41392-023-01548-8","article-title":"A new wave of innovations within the DNA damage response","volume":"8","author":"Li","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"2025110311355120200_B153","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1200\/JCO.2020.38.15_suppl.3581","article-title":"A phase ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer","volume":"38","author":"Chu","year":"2020","journal-title":"JCO"},{"key":"2025110311355120200_B154","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1200\/JCO.2020.38.15_suppl.3579","article-title":"A phase ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer","volume":"38","author":"Miller","year":"2020","journal-title":"JCO"},{"key":"2025110311355120200_B155","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-23-2005","article-title":"A phase I expansion cohort study evaluating the safety and efficacy of the CHK1 inhibitor LY2880070 with low-dose Gemcitabine in patients with metastatic pancreatic adenocarcinoma","volume":"29","author":"Huffman","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025110311355120200_B156","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2020.12.015","article-title":"Structure of an activated DNA-PK and its implications for NHEJ","volume":"81","author":"Chen","year":"2021","journal-title":"Mol Cell"},{"key":"2025110311355120200_B157","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1126\/science.aak9654","article-title":"DNA-PKcs structure suggests an allosteric mechanism modulating DNA double-strand break repair","volume":"355","author":"Sibanda","year":"2017","journal-title":"Science"},{"key":"2025110311355120200_B158","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.molcel.2021.11.025","article-title":"Autophosphorylation transforms DNA-PK from protecting to processing DNA ends","volume":"82","author":"Liu","year":"2022","journal-title":"Mol Cell"},{"key":"2025110311355120200_B159","doi-asserted-by":"publisher","first-page":"e74700","DOI":"10.7554\/eLife.74700","article-title":"DNA-PK promotes DNA end resection at DNA double strand breaks in G0 cells","volume":"11","author":"Fowler","year":"2022","journal-title":"eLife"},{"key":"2025110311355120200_B160","doi-asserted-by":"publisher","first-page":"8255","DOI":"10.1038\/s41598-019-44771-6","article-title":"Radiation-dose-dependent functional synergisms between ATM, ATR and DNA-PKcs in checkpoint control and resection in G2-phase","volume":"9","author":"Mladenov","year":"2019","journal-title":"Sci Rep"},{"key":"2025110311355120200_B161","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41598-021-04618-5","article-title":"Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer","volume":"12","author":"Gordhandas","year":"2022","journal-title":"Sci Rep"},{"key":"2025110311355120200_B162","doi-asserted-by":"publisher","first-page":"zcaa038","DOI":"10.1093\/narcan\/zcaa038","article-title":"Dual inhibition of DNA-PK and DNA polymerase theta overcomes radiation resistance induced by p53 deficiency","volume":"2","author":"Kumar","year":"2020","journal-title":"NAR Cancer"},{"key":"2025110311355120200_B163","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1158\/1078-0432.CCR-20-3701","article-title":"Inhibition of DNA-PK with AZD7648 sensitizes tumor cells to radiotherapy and induces type I IFN-dependent durable tumor control","volume":"27","author":"Nakamura","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025110311355120200_B164","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1158\/1541-7786.MCR-21-0612","article-title":"DNA-PK inhibitor Peposertib amplifies radiation-induced inflammatory micronucleation and enhances tgf\u03b2\/PD-L1 targeted cancer immunotherapy","volume":"20","author":"Carr","year":"2022","journal-title":"Mol Cancer Res"},{"key":"2025110311355120200_B165","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1158\/0008-5472.CAN-21-1756","article-title":"DNA-PKcs: a targetable protumorigenic protein kinase","volume":"82","author":"Dylgjeri","year":"2022","journal-title":"Cancer Res"},{"key":"2025110311355120200_B166","doi-asserted-by":"publisher","first-page":"5065","DOI":"10.1038\/s41467-019-12836-9","article-title":"AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity","volume":"10","author":"Fok","year":"2019","journal-title":"Nat Commun"},{"key":"2025110311355120200_B167","doi-asserted-by":"publisher","first-page":"eadg2263","DOI":"10.1126\/sciadv.adg2263","article-title":"ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer","volume":"9","author":"Zhou","year":"2023","journal-title":"Sci Adv"},{"key":"2025110311355120200_B168","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1158\/1535-7163.MCT-19-0734","article-title":"Pharmacologic inhibitor of DNA-PK, M3814, potentiates radiotherapy and regresses Human tumors in mouse models","volume":"19","author":"Zenke","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2025110311355120200_B169","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/1541-7786.MCR-19-0362","article-title":"Therapeutic implications of p53 status on cancer cell fate following exposure to ionizing radiation and the DNA-PK inhibitor M3814","volume":"17","author":"Sun","year":"2019","journal-title":"Mol Cancer Res"},{"key":"2025110311355120200_B170","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ijrobp.2023.09.024","article-title":"A phase 1 study of the DNA-PK inhibitor Peposertib in combination with radiation therapy with or without cisplatin in patients with advanced head and neck tumors","volume":"118","author":"Samuels","year":"2024","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"2025110311355120200_B171","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1158\/1078-0432.CCR-23-1129","article-title":"A Phase ib study of the DNA-PK inhibitor Peposertib combined with neoadjuvant chemoradiation in patients with locally advanced rectal cancer","volume":"30","author":"Romesser","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025110311355120200_B172","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1158\/1535-7163.MCT-23-0402","article-title":"The novel ATR inhibitor Tuvusertib (M1774) induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs","volume":"23","author":"Jo","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"2025110311355120200_B173","doi-asserted-by":"publisher","first-page":"102217","DOI":"10.1016\/j.esmoop.2023.102217","article-title":"Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors","volume":"9","author":"Perez","year":"2024","journal-title":"ESMO Open"},{"key":"2025110311355120200_B174","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/s41467-019-08859-x","article-title":"Emerging roles of eraser enzymes in the dynamic control of protein ADP-ribosylation","volume":"10","author":"O\u2019Sullivan","year":"2019","journal-title":"Nat Commun"},{"key":"2025110311355120200_B175","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.dnarep.2015.04.008","article-title":"The rise and fall of poly(ADP-ribose): an enzymatic perspective","volume":"32","author":"Pascal","year":"2015","journal-title":"DNA Repair"},{"key":"2025110311355120200_B176","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/j.str.2024.09.006","article-title":"PARG inhibition induces nuclear aggregation of PARylated PARP1","volume":"32","author":"Paradkar","year":"2024","journal-title":"Structure"},{"key":"2025110311355120200_B177","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev"},{"key":"2025110311355120200_B178","doi-asserted-by":"publisher","first-page":"e2413954121","DOI":"10.1073\/pnas.2413954121","article-title":"PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer","volume":"121","author":"Ravindranathan","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025110311355120200_B179","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ccell.2019.02.004","article-title":"DNA replication vulnerabilities render ovarian cancer cells sensitive to poly(ADP-Ribose) glycohydrolase inhibitors","volume":"35","author":"Pillay","year":"2019","journal-title":"Cancer Cell"},{"key":"2025110311355120200_B180","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s13046-021-02124-0","article-title":"Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models","volume":"40","author":"Coulson-Gilmer","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2025110311355120200_B181","doi-asserted-by":"publisher","first-page":"6093","DOI":"10.1158\/1538-7445.AM2023-6093","article-title":"Abstract 6093: IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets homologous-recombination-deficient and PARP inhibitor resistant breast and ovarian tumors","volume":"83","author":"Abed","year":"2023","journal-title":"Cancer Res"},{"key":"2025110311355120200_B182","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1158\/1538-7445.AM2024-2083","article-title":"Abstract 2083: discovery of ETX-19477, a novel and selective PARG inhibitor with high potency against tumors with underlying replication stress","volume":"84","author":"Holleran","year":"2024","journal-title":"Cancer Res"},{"key":"2025110311355120200_B183","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","article-title":"DNA topoisomerases and their poisoning by anticancer and antibacterial drugs","volume":"17","author":"Pommier","year":"2010","journal-title":"Chem Biol"},{"key":"2025110311355120200_B184","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/bjc.2011.498","article-title":"Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets","volume":"106","author":"Gilbert","year":"2012","journal-title":"Br J Cancer"},{"key":"2025110311355120200_B185","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cyto.a.21172","article-title":"Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin\/topotecan, mitoxantrone, or etoposide","volume":"81A","author":"Zhao","year":"2012","journal-title":"Cytometry Pt A"},{"key":"2025110311355120200_B186","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2025110311355120200_B187","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1021\/jm049146p","article-title":"Structures of three classes of anticancer agents bound to the Human topoisomerase I\u2212DNA covalent complex","volume":"48","author":"Staker","year":"2005","journal-title":"J Med Chem"},{"key":"2025110311355120200_B188","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s002800000180","article-title":"Phase I study of docetaxel and topotecan in patients with solid tumors","volume":"46","author":"Tkaczuk","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025110311355120200_B189","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3816\/CLC.2008.n.023","article-title":"A randomized phase II trial of oral Topotecan versus Docetaxel in the second-line treatment of non\u2013small-cell lung cancer","volume":"9","author":"Jones","year":"2008","journal-title":"Clin Lung Cancer"},{"key":"2025110311355120200_B190","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1097\/JTO.0b013e3181d86a4f","article-title":"A Phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer","volume":"5","author":"Spigel","year":"2010","journal-title":"J Thorac Oncol"},{"key":"2025110311355120200_B191","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ygyno.2023.01.010","article-title":"Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: an NRG oncology randomized study","volume":"171","author":"Tewari","year":"2023","journal-title":"Gynecol Oncol"},{"key":"2025110311355120200_B192","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1200\/jco.2008.26.15_suppl.4109","article-title":"LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin: results of CALGB 80402","volume":"26","author":"Ocean","year":"2008","journal-title":"JCO"},{"key":"2025110311355120200_B193","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/path.6055","article-title":"SN-38, an active metabolite of irinotecan, enhances anti-PD-1 treatment efficacy in head and neck squamous cell carcinoma","volume":"259","author":"Lee","year":"2023","journal-title":"J Pathol"},{"key":"2025110311355120200_B194","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/oncolo\/oyab025","article-title":"Cetuximab and Irinotecan with or without Bevacizumab in refractory metastatic colorectal cancer: BOND-3, an ACCRU network randomized clinical trial","volume":"27","author":"Lipsyc-Sharf","year":"2022","journal-title":"Oncologist"},{"key":"2025110311355120200_B195","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1016\/j.ejca.2013.06.017","article-title":"A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)","volume":"49","author":"Middleton","year":"2013","journal-title":"Eur J Cancer"},{"key":"2025110311355120200_B196","doi-asserted-by":"crossref","first-page":"975926","DOI":"10.3389\/fimmu.2022.975926","article-title":"Targeting 4-1BB for tumor immunotherapy from bench to bedside","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"2025110311355120200_B197","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1158\/1078-0432.CCR-16-1274","article-title":"A phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms, and chronic myelomonocytic leukemia","volume":"23","author":"Pratz","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025110311355120200_B198","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1158\/1535-7163.MCT-22-0217","article-title":"PLX038: a long-acting topoisomerase I inhibitor with robust antitumor activity in ATM-deficient tumors and potent synergy with PARP inhibitors","volume":"21","author":"Thomas","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2025110311355120200_B199","doi-asserted-by":"publisher","first-page":"TPS5630","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5630","article-title":"Phase II clinical trial of PLX038 in patients with platinum resistant ovarian, primary peritoneal and fallopian tube cancer","volume":"42","author":"Hendrickson","year":"2024","journal-title":"JCO"},{"key":"2025110311355120200_B200","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3390\/jcm10071416","article-title":"Prioritization of novel agents for patients with rhabdomyosarcoma: a report from the children\u2019s oncology group (COG) New Agents for rhabdomyosarcoma Task Force","volume":"10","author":"Pacenta","year":"2021","journal-title":"JCM"},{"key":"2025110311355120200_B201","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41586-019-1102-x","article-title":"WRN helicase is a synthetic lethal target in microsatellite unstable cancers","volume":"568","author":"Chan","year":"2019","journal-title":"Nature"},{"key":"2025110311355120200_B202","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1101\/gad.351084.123","article-title":"ATR inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy","volume":"37","author":"Wang","year":"2023","journal-title":"Genes Dev"},{"key":"2025110311355120200_B203","doi-asserted-by":"publisher","first-page":"e2211775119","DOI":"10.1073\/pnas.2211775119","article-title":"Synthetical lethality of Werner helicase and mismatch repair deficiency is mediated by p53 and PUMA in colon cancer","volume":"119","author":"Hao","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025110311355120200_B204","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1101\/gad.351085.123","article-title":"Comprehensive mapping of cell fates in microsatellite unstable cancer cells supports dual targeting of WRN and ATR","volume":"37","author":"Zong","year":"2023","journal-title":"Genes Dev"},{"key":"2025110311355120200_B205","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-024-07350-y","article-title":"Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers","volume":"629","author":"Ferretti","year":"2024","journal-title":"Nature"},{"key":"2025110311355120200_B206","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41586-024-07318-y","article-title":"Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase","volume":"629","author":"Baltgalvis","year":"2024","journal-title":"Nature"},{"key":"2025110311355120200_B207","doi-asserted-by":"publisher","first-page":"117039","DOI":"10.1016\/j.ejmech.2024.117039","article-title":"Design, synthesis, and structure\u2013activity relationship studies of triazolo-pyrimidine derivatives as WRN inhibitors for the treatment of MSI tumors","volume":"282","author":"Sui","year":"2025","journal-title":"Eur J Med Chem"},{"key":"2025110311355120200_B208","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s10238-025-01781-1","article-title":"Targeting the Werner syndrome protein in microsatellite instability cancers: mechanisms and therapeutic potential","volume":"25","author":"Chen","year":"2025","journal-title":"Clin Exp Med"},{"key":"2025110311355120200_B209","doi-asserted-by":"publisher","first-page":"zcad042","DOI":"10.1093\/narcan\/zcad042","article-title":"Alkylation of nucleobases by 2-chloro-N,N-diethylethanamine hydrochloride (CDEAH) sensitizes PARP1-deficient tumors","volume":"5","author":"Wie","year":"2023","journal-title":"NAR Cancer"},{"key":"2025110311355120200_B210","doi-asserted-by":"publisher","first-page":"e2103532119","DOI":"10.1073\/pnas.2103532119","article-title":"Precision targeting tumor cells using cancer-specific InDel mutations with CRISPR\u2013Cas9","volume":"119","author":"Kwon","year":"2022","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["NAR Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/narcancer\/article-pdf\/7\/4\/zcaf040\/65131379\/zcaf040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/narcancer\/article-pdf\/7\/4\/zcaf040\/65131379\/zcaf040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:36:03Z","timestamp":1762187763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/narcancer\/article\/doi\/10.1093\/narcan\/zcaf040\/8313449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":210,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/narcan\/zcaf040","relation":{},"ISSN":["2632-8674"],"issn-type":[{"value":"2632-8674","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,7]]},"article-number":"zcaf040"}}